These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31289316)

  • 41. Targeting glutamine metabolism in myeloproliferative neoplasms.
    Zhan H; Ciano K; Dong K; Zucker S
    Blood Cells Mol Dis; 2015 Oct; 55(3):241-7. PubMed ID: 26227854
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
    Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
    Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells.
    D'Alise AM; Amabile G; Iovino M; Di Giorgio FP; Bartiromo M; Sessa F; Villa F; Musacchio A; Cortese R
    Mol Cancer Ther; 2008 May; 7(5):1140-9. PubMed ID: 18483302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
    Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
    J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
    Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J; Robak T
    Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.
    Takei H; Coelho-Silva JL; Tavares Leal C; Queiroz Arantes Rocha A; Mantello Bianco T; Welner RS; Mishima Y; Kobayashi IS; Mullally A; Lima K; Machado-Neto JA; Kobayashi SS; Lobo de Figueiredo-Pontes L
    Cancer Sci; 2022 Feb; 113(2):597-608. PubMed ID: 34808021
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2
    Fernandes JC; Fenerich BA; Alves-Silva AB; Fonseca NP; Coelho-Silva JL; Scheucher PS; Rego EM; Figueiredo-Pontes LL; Machado-Neto JA; Traina F
    Toxicol In Vitro; 2022 Sep; 83():105384. PubMed ID: 35568132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.
    Rampal RK; Pinzon-Ortiz M; Somasundara AVH; Durham B; Koche R; Spitzer B; Mowla S; Krishnan A; Li B; An W; Derkach A; Devlin S; Rong X; Longmire T; Eisman SE; Cordner K; Whitfield JT; Vanasse G; Cao ZA; Levine RL
    Clin Cancer Res; 2021 Jun; 27(12):3456-3468. PubMed ID: 33782031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia.
    Moreira-Nunes CA; Mesquita FP; Portilho AJS; Mello Júnior FAR; Maués JHDS; Pantoja LDC; Wanderley AV; Khayat AS; Zuercher WJ; Montenegro RC; de Moraes-Filho MO; de Moraes MEA
    Sci Rep; 2020 Dec; 10(1):21272. PubMed ID: 33277547
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.
    Amaru Calzada A; Pedrini O; Finazzi G; Leoni F; Mascagni P; Introna M; Rambaldi A; Golay J;
    Exp Hematol; 2013 Mar; 41(3):253-60.e2. PubMed ID: 23111067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].
    Liu GM; Zhang LJ; Fu JZ; Liang WT; Cheng ZY; Bai P; Bian YS; Wan JS
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):140-145. PubMed ID: 28279039
    [No Abstract]   [Full Text] [Related]  

  • 54. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
    Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
    Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Loss of Tyrosine Kinase 2 Does Not Affect the Severity of
    Yamaji T; Shide K; Kameda T; Sekine M; Kamiunten A; Hidaka T; Kubuki Y; Shimoda H; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Shimoda K
    Anticancer Res; 2017 Jul; 37(7):3841-3847. PubMed ID: 28668884
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myeloproliferative and lymphoproliferative disorders: State of the art.
    Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
    Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relation of
    Huang D; Huang Y; Huang Z; Weng J; Zhang S; Gu W
    Cancer Cell Int; 2019; 19():166. PubMed ID: 31244554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.
    Yang J; Weisberg EL; Liu X; Magin RS; Chan WC; Hu B; Schauer NJ; Zhang S; Lamberto I; Doherty L; Meng C; Sattler M; Cabal-Hierro L; Winer E; Stone R; Marto JA; Griffin JD; Buhrlage SJ
    Leukemia; 2022 Jan; 36(1):210-220. PubMed ID: 34326465
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effect of IFN-α2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms].
    Zhao YL; Zhang LJ; Fu JZ; Xu Q; Liu GM; Xie XL; Liang WT; Cheng ZY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Jul; 47(4):473-478. PubMed ID: 28591945
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [JAK2-V617F mutation in patients with myeloproliferative neoplasms: association with FLT3-ITD mutation].
    Spasovski V; Tosić N; Kostić T; Pavlović S; Colović M
    Srp Arh Celok Lek; 2010; 138(9-10):614-8. PubMed ID: 21180092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.